


JC20 Rec'd PCT/PTO 23 AUG 2001

FORM PTO-1390 (REV 12-29-99)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER YAM 2 0009	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/914340	
INTERNATIONAL APPLICATION NO. PCT/JP00/01049		INTERNATIONAL FILING DATE 23 February 2000		PRIORITY DATE CLAIMED 26 February 1999	
TITLE OF INVENTION CHEWABLE SOFT CAPSULE HAVING IMPROVED INGESTION PROPERTY AND METHOD FOR PRODUCING SAME					
APPLICANT(S) FOR DO/EO/US SHODAI et al.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> have been transmitted by the International Bureau. (Article 34 copy enclosed) c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input checked="" type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). (Article 34) 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Unexecuted) 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11. to 16. below concern document(s) or information included:					
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information: 					
<div style="text-align: right;"> <p>"Express Mail" Mailing Label Number <u>EL 852681527 US</u></p> <p>Date of Deposit <u>August 23, 2001</u></p> <p>I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</p> <p><u>LAURIE A. BOYLAN</u> (TYPED OR PRINTED NAME OF SENDER)</p> <p><u>Laurie A. Boylan</u> (S. NATURE)</p> </div>					

U.S. APPLICATION NO. (If known, use 37 CFR 1.57) 09/914340		INTERNATIONAL APPLICATION NO. PCT/JP00/01049		ATTORNEY'S DOCKET NUMBER YAM 2 0009	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	40 - 20 =	20	X \$18.00	\$ 360.00	
Independent claims	1 - 3 =	0	X \$78.00	\$ 80.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$260.00	\$ 270.00
TOTAL OF ABOVE CALCULATIONS =				\$ 710.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$1,570.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$1,570.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property . . . +				\$	
TOTAL FEES ENCLOSED =				\$1,570.00	
				Amount to be: refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1,570.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-0308</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Richard M. Klein FAY, SHARPE, FAGAN, MINNICH & MCKEE, LLP 1100 Superior Avenue, Seventh Floor Cleveland, OH 44114 RKlein@faysharpe.com (216) 861-5582					
				SIGNATURE:  Richard M. Klein NAME 33,000 REGISTRATION NUMBER Fay, Sharpe et al. 1100 Superior Ave., Seventh Floor Cleveland, OH 44114	

"Express Mail" Mailing Label Number EL 852681527 US
Date of Deposit August 23 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

LAURIE A. BOYLAN
(TYPED OR PRINTED NAME OF SENDER)
Laurie A. Boylan
(SI. NATURE)

09/914340

JC03 Rec'd PCT/PTO 23 AUG 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
SHODAI ET AL.

International Application No. PCT/JP00/01049
International Filing Date February 23, 2000

For: CHEWABLE SOFT CAPSULE HAVING
IMPROVED INGESTION PROPERTY
AND METHOD FOR PRODUCING SAME

Attorney Docket No. YAM 2 0009

Cleveland, Ohio 44114
August 23, 2001

PRELIMINARY AMENDMENT

BOX Application
Commissioner for Patents
Washington, DC 20231

Dear Sir:

Prior to the examination of the merits and/or calculation of the fees, kindly amend the above-identified application as follows:

In the Claims:

Please amend claims 19, 24, 27, and 28 as follows:

19. A soft capsule according to claim 1, wherein

the shell comprises the following components (A) and (B):

(A) gelatin; and

206T20" 04E4T660

(B) one or more plasticizers selected from (b1) to (b3), wherein a total of 100 to 600 weight parts of the plasticizers is present in the shell with respect to 100 weight parts of gelatin:

(b1) glycerin,

(b2) saccharide plasticizer selected from the group consisting of sucrose, fructose, D-mannitol, xylitol, erythritol, D-sorbitol, maltose, reduced maltose syrup, maltitol, sucrose alcohol and isomerized sugar as well as a combination thereof, and

(b3) glycol selected from the group consisting of propylene glycol and polyethylene glycol as well as a combination thereof.

24. A soft capsule according to claim 1, wherein the fill material comprises a drug.

27. A soft capsule according to claim 1, wherein the fill material comprises a food.

28. A method for producing a soft capsule according to claim 1, comprising the step of:

filling the shell with the fill material.


REMARKS

The present application has been amended in order to reduce the number of multiple dependent claims. This is solely for procedural reasons and does not reflect the scope of the overall invention. Entry of this preliminary amendment is requested at the U.S. Patent and Trademark Office's earliest convenience.

Respectfully submitted,

FAY, SHARPE, FAGAN, MINNICH
& McKEE, LLP

By:



Richard M. Klein
Reg. No. 33,000
1100 Superior Avenue
Seventh Floor
Cleveland, Ohio 44114
Telephone: 216-861-5582
Facsimile: 216-241-1666
E-mail: rklein@faysharpe.com

N:\YAM\20009\LAB0132A.WPD

Mark-up of Amendments to Application

Please amend claims 19, 24, 27, and 28 as follows:

19. (Amended) A soft capsule according to [any of claims 1 to 18] claim 1,

wherein

the shell comprises the following components (A) and (B):

(A) gelatin; and

(B) one or more plasticizers selected from (b1) to (b3), wherein a total of 100 to 600 weight parts of the plasticizers is present in the shell with respect to 100 weight parts of gelatin:

(b1) glycerin,

(b2) saccharide plasticizer selected from the group consisting of sucrose, fructose, D-mannitol, xylitol, erythritol, D-sorbitol, maltose, reduced maltose syrup, maltitol, sucrose alcohol and isomerized sugar as well as a combination thereof, and

(b3) glycol selected from the group consisting of propylene glycol and polyethylene glycol as well as a combination thereof.

24. (Amended) A soft capsule according to [any of claims 1 to 23] claim 1,

wherein the fill material comprises a drug.

27. (Amended) A soft capsule according to [any of claims 1-23] claim 1,

wherein the fill material comprises a food.

28. (Amended) A method for producing a soft capsule according to [any of claims 1-27] claim 1, comprising the step of:

filling the shell with the fill material.

0914340.021902

4/18/85

09/914340
JC03 Rec'd F... TO 23 AUG 2001

- 1 -

SO040

DESCRIPTION

CHEWABLE SOFT CAPSULE HAVING IMPROVED INGESTION PROPERTY
AND METHOD FOR PRODUCING SAME

5

TECHNICAL FIELD

The present invention relates to a chewable soft capsule and a method for producing the same. More particularly, the present invention relates to a soft capsule whose fill material is in a solid or semi-solid form at room temperature, and a method for producing the same.

10

BACKGROUND ART

15

Recently, there has been increasing demand for chewable capsules which can be easily ingested without water from a viewpoint of improving ingestion properties and portability of pharmaceuticals. Chewable capsules capable of being easily ingested without water are useful especially as immediate-soluble preparations for children and the elderly.

20

One of the dosage forms which can be used as a chewable preparation is a soft capsule. As a method for softening the shell of a soft capsule to be made suitable for chewing, a method for increasing the mix proportion of a plasticizer, such as concentrated glycerin, glycerin, or D-sorbitol, in the composition of the shell is conventionally known (e.g., see Japanese Laid-Open Publication No. 10-273436 and WO87/01034). However, as the conventional fill material of a soft capsule, an oil solution or suspension, an aqueous or alcoholic solution, or the like

25

30

09/914340-21903

have been used. These fill materials are heterogeneous to the shell of a soft capsule. Therefore, when chewing, such a capsule is likely to leave an unpleasant sensation from the shell and the oiliness of an oil base in a fill material.

5 Drugs often exhibit an unpleasant taste, such as peculiar bitterness. Since the drug-containing fill material of conventional chewable soft capsules is in a solution or suspension form, the fill material immediately spreads out in the mouth and the bitterness of the drug is sensed

10 simultaneously with the ingestion of the capsules. This leads to a reduction in the sensation of ingestion of soft capsules.

In the case of tablets, in order to improve the sensation of ingestion, there has been reported a method for producing a tablet using granules comprising oils and fats so as to be immediately disintegrated in the mouth (see Japanese Laid-Open Publication No. 8-333243). However,

15 there is no known soft capsule which has been known to be improved in the sensation of ingestion from the above-described viewpoint.

20

In the field of foods, recently, as there has been a growing interest in health, there are increasing needs for chewable capsules via which nutrients can be easily

25 supplied. Therefore, soft capsules having an excellent sensation of ingestion are useful for applications as foods and so on, in addition to medications.

As described above, conventional chewable soft capsules are not necessarily satisfactory in terms of the sensation of ingestion due to an unpleasant sensation from the shell and the bitterness of the drugs. The present

30

invention is intended to solve the above-described problems.

DISCLOSURE OF THE INVENTION

5

As a result of vigorous study by the inventors, it was found that when a soft capsule is formulated in such a manner that the fill material is in a solid or semi-solid form at room temperature, the shell and the fill material homogenized with each other when the capsule is chewed, so that an unpleasant sensation from the shell is alleviated. Particularly, the fill material of the soft capsule is preferably a low melting point additive. Specifically, when a chocolate base, such as cacao powder, bitter chocolate, or cacao butter, is formulated at an appropriate mix portion, a chewable formulation which can be easily chewed in the mouth without water can be obtained. The present invention is completed based on these findings.

20

According to the present invention, a soft capsule comprising fill material filling a shell is provided. The fill material is in a solid or semi-solid form at room temperature.

25

In one embodiment of this invention, the soft capsule is a chewable capsule.

In one embodiment of this invention, the fill material comprises a low melting point additive. The content of the low melting point additive is 10% or more, preferably 30% or more, and more preferably 50% or more with respect to the total weight of the fill material. Further, the melting point of the low melting point additive is about

094440.02490

20 to 50°C.

5 The above-described low melting point additive may be selected from the group consisting of chocolate base, lard, coconut oil and macrogol (polyethylene glycol) as well as a combination thereof. Particularly, the low melting point additive is preferably a chocolate base which may be selected from the group consisting of cacao powder, bitter chocolate and cacao butter as well as a combination thereof. 10 Preferably, the cacao butter may include a major amount of V-type crystal and a minor amount of VI-type crystal.

15 In one embodiment of this invention, the fill material further comprises a sweetening agent. The sweetening agent may be selected from the group consisting of aspartame, disodium glycyrrhizinate, saccharin sodium, stevia and thaumatin as well as a combination thereof.

20 In one embodiment of this invention, in the soft capsule of the invention, the fill material comprises cacao butter as chocolate base, which is a low melting point additive, and aspartame as a sweetening agent.

25 In one embodiment of this invention, in the soft capsule of the invention, the fill material further comprise a saccharide in addition to the sweetening agent. The saccharide may be selected from the group consisting of sucrose, D-mannitol, xylitol, erythritol, D-sorbitol, maltose, reduced maltose syrup and maltitol as well as a 30 combination thereof.

In one embodiment of this invention, in the soft capsule of the invention, the fill material further comprise

an aromatic in addition to the sweetening agent. The aromatic may be chocolate flavor.

5 In one embodiment of this invention, in the soft capsule of the invention, the shell comprises the following components (A) and (B): (A) gelatin; and (B) one or more plasticizers selected from (b1) to (b3), in which a total of 100 to 600 weight parts of the plasticizers is present in the shell with respect to 100 weight parts of gelatin:
10 (b1) glycerin, (b2) saccharide plasticizer selected from the group consisting of sucrose, fructose, D-mannitol, xylitol, erythritol, D-sorbitol, maltose, reduced maltose syrup, maltitol, sucrose alcohol and isomerized sugar as well as a combination thereof, and (b3) glycol selected from
15 the group consisting of propylene glycol and polyethylene glycol as well as a combination thereof. The plasticizers (B) may include the glycerin (b1). The shell may further comprise (C) water-insoluble cellulose in addition to (A) and (B), in which 5 to 100 weight parts of
20 water-insoluble cellulose is present in the shell with respect to 100 weight parts of the gelatin.

In one embodiment of this invention, in the soft capsule of the invention, the shell further comprise (D)
25 a sweetener in addition to (A) and (B). The sweetener (D) may be selected from the group consisting of saccharin sodium, stevia and thaumatin as well as a combination thereof.

In one embodiment of this invention, in the soft
30 capsule of the invention, the fill material comprises a drug. The content of the drug may be 60% or less with respect to the total weight of the fill material.

0914340.021902

5 In one embodiment of this invention, in the soft capsule of the invention, the drug is selected from the group consisting of an antipyretic analgesic drug component, a rhinitis drug component, an antitussive expectorant drug component and a vitamin component as well as a combination thereof.

10 In one embodiment of this invention, in the soft capsule of the invention, the fill material comprises a food.

15 Further, according to the present invention, a method for producing any of the above-described soft capsules comprising the step of filling the shell with the fill material is provided.

20 In one embodiment of this invention, in the method, the fill material comprises cacao butter as chocolate base, which is a low melting point additive, and the method further comprises the step of subjecting the fill material filling in the shell to aging at a temperature of 30 to 40°C. The aging could be conducted for 10 hours or more.

BRIEF DESCRIPTION OF THE DRAWINGS

25 Figure 1 is a process diagram showing an example of production of a soft capsule of the present invention.

30 Figure 2 is a graph showing the change in hardness of capsule fill material and cacao butter with respect to aging temperature. The vertical axis represents hardness (kgs), while the horizontal axis represents aging temperature (°C). Black triangles represent results for the capsule fill material. Black diamonds represent results

for cacao butter alone.

Figure 3 is a graph showing the change in hardness of capsule fill material and cacao butter with respect to aging time. The vertical axis represents hardness (kgs), while the horizontal axis represents aging time at 35°C. Black triangles represent results for the capsule fill material. Black diamonds represent results for cacao butter alone.

Figure 4 is a graph showing the results of a taste test and a usability test for soft capsules produced with or without aging. The vertical axis represents mean values for each item judged by five volunteers in a five-level evaluation. The four left-hand columns (products before improvement) show results without aging, while right four columns (improved products) show results with aging. The columns represent, from left, the unpleasant sensation from the shell, the bitterness of the fill material, the total sensation of ingestion, and usability.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention will be described in more detail.

A soft capsule of the present invention is characterized by comprising a shell into which a fill material comprising a drug or a food is filled, and in that the fill material is in a solid or semi-solid form at room temperature. "Room temperature" refers to about 1 to 30°C. "In a solid or semi-solid form" refers to that a fill material substantially does not exhibit a flow property at room

temperature. A fill material may be in a powder form, and more preferably in an integrated solid or semi-solid form.

5 According to the present invention, since a fill material of a soft capsule is in a solid or semi-solid form, the fill material and a shell homogenize with each other in the mouth when chewing the capsule. Therefore, the unpleasant sensation typical of shells can be alleviated and the oiliness of the oil base is not sensed, thereby
10 significantly improving the sensation of ingestion.

The soft capsule of the present invention comprising a fill material in a solid or semi-solid form at room temperature is novel. Although embodiments of use thereof
15 are not specifically limited, a preferable embodiment thereof is a chewable capsule.

In the soft capsule of the present invention, the fill material may comprise a low melting point additive.
20 The addition of an appropriate amount of the low melting point additive allows the entire fill material to be melted without undue heating. Therefore, the soft capsule can be easily produced without degeneration or decomposition of fill material components, such as a drug and a food, and
25 without the occurrence of adhesion failure of the capsule.

The proportion of the low melting point additive is not particularly limited, and may be typically 10% or more, preferably 20% or more, more preferably 30% or more, even
30 more preferably 40% or more, further preferably 50% or more, and even further 60% or more with respect to the total weight of fill material. The low melting point additive is preferably an additive capable of adjusting the dissolving

09914340-021902

temperature of the entire base for the fill material comprising the additive to higher than room temperature, and typically about 70°C or less, preferably about 60°C or less, more preferably about 50°C or less, and even more preferably about 45°C or less. "Base" refers to a fill material other than a drug in the case of a soft capsule comprising the drug, and a component of a fill material other than a food in the case of a soft capsule comprising the food.

The low melting point additive may be any additive which is pharmaceutically acceptable or appropriate for foods as long as the above-described objectives can be achieved. The melting point of such a low melting point additive may be typically in the range of about 20 to 50°C, preferably about 25 to 45°C, and more preferably about 30 to 40°C.

Preferable examples of the low melting point additive include chocolate base, lard, coconut oil and macrogol (polyethylene glycol) as well as any combination thereof. Particularly, when macrogol is used, the solubility and release properties of a slightly-soluble drug can be improved, and the absorbability of a slightly-absorbable drug can be improved. These additives are commercially available, or can be readily produced using a known preparation method. Examples of commercially available macrogol which may be preferably used in the present invention include macrogol 600, macrogol 1000, macrogol 1500, and macrogol 1540.

The chocolate base refers to known materials which can be raw materials for chocolate as well as a combination

thereof. Typical chocolate bases include cacao powder, bitter chocolate, and cacao butter as well as a combination thereof. Cacao powder, bitter chocolate and cacao butter are all known as pharmaceutical additives.

5

By including a chocolate base in a fill material as needed, a chocolate-flavor preparation can be provided which keeps appearance as a capsule and which can be easily chewed in the mouth without water. Further, unpleasant tastes due to the drug or food will be masked.

10

Also, in the soft capsule of the present invention, the fill material may comprise any sweetening component which is pharmaceutically acceptable or appropriate as a food (herein referred to as a "sweetening agent"). Preferable examples of the sweetening agent include aspartame, disodium glycyrrhizinate, saccharin sodium, stevia and thaumatin as well as any combination thereof. For the sake of convenience, saccharides (described later) which may be contained in the fill material are excluded from the definition of sweetening agents.

15

20

By including a sweetening agent in a fill material as needed, it is possible to provide a preparation further suppressing unpleasant tastes, such as the bitterness of a drug or food.

25

The inventors have found that when cacao butter as a chocolate base is combined with aspartame as a sweetening agent, an aspartame stabilizing effect is obtained. Therefore, a soft capsule comprising a fill material comprising cacao butter as a chocolate base and aspartame as a sweetening agent is a preferred embodiment of the

30

05914340-024002

invention. The above-described stabilizing effect may be significant, especially when formulated in a mix proportion of cacao butter which is typically about 5% or more, and preferably about 10% to 50% with respect to the total weight of the fill material, or typically about 3 to 15 weight parts, and preferably about 3 to 12 weight parts with respect to one weight part of aspartame.

Also, in the soft capsule of the present invention, the fill material may comprise any saccharide, which is pharmaceutically acceptable or appropriate as a food, in addition to a sweetening agent. Preferable examples of a saccharide include sucrose, D-mannitol, xylitol, erythritol, D-sorbitol, maltose, reduced maltose syrup and maltitol as well as any combination thereof. Sugar alcohols are generally stable toward drugs and foods and therefore are especially preferable examples of a saccharide. For the sake of convenience, glycosides exhibiting sweetness, such as stevia described above, are excluded from the definition of saccharides.

Also, in the soft capsule of the present invention, the fill material may comprise any aromatic, which is pharmaceutically acceptable or appropriate as a food, in addition to a sweetening agent. Preferable examples of an aromatic include chocolate flavor, peppermint flavor and vanilla flavor as well as any combination thereof.

By including a saccharide and/or an aromatic in addition to a sweetening agent into a fill material as needed, it is possible to provide a soft capsule having a further improved sensation of ingestion.

In the soft capsule of the present invention, the fill material typically comprises a drug or a food.

5 In the soft capsule of the present invention, the content of the drug may be typically 60% or less, preferably 50% or less, more preferably 30% or less, and even more preferably 15% or less with respect to the total weight of fill material. Restricting the amount of a drug to a relatively low value makes it possible to provide a
10 preparation wherein the unpleasant taste of the drug is especially alleviated.

Examples of a drug used in the soft capsule of the present invention include, but are not limited to, an
15 antipyretic analgesic drug component, a rhinitis drug component, an antitussive expectorant drug component, and a vitamin component as well as a combination thereof. Examples of an antipyretic analgesic drug component include acetaminophen, aspirin, ethenzamide, salicylamide, and
20 lactylphenetidine. Examples of a rhinitis drug component include phenylpropanolamine hydrochloride, d-chlorpheniramine maleate, dipotassium glycyrrhizinate, and belladonna leaf alkaloids. Examples of an antitussive expectorant drug component include dextromethorphan
25 hydrobromide, codeine phosphate, methoxyphenamine hydrochloride, ephedra herb, and glycyrrhiza. Examples of a vitamin component include water-soluble vitamins, such as vitamin B and vitamin C, and fat-soluble vitamins, such as vitamin A and vitamin D. As described above, the present
30 invention can be used preferably to provide a soft capsule for a drug having an unpleasant taste, particularly bitterness.

09914340-024902

5 In the soft capsule of the present invention, the content of food may be typically 80% or less, preferably 70% or less, more preferably 50% or less, and even more preferably 30% or less with respect to the total weight of fill material.

10 Examples of a food used in the soft capsule of the present invention include, but are not limited to, any protein, peptide, or lipid (including steroid, carotenoid, and terpenoids), and sugars, and derivatives thereof; dried powders and extracts of any edible plant, animal, bacterium, and fungus; as well as a combination thereof.

15 Examples of proteins include enzymes, antibodies and collagen. Examples of enzymes include pepsine, trypsin, amylase, lipase and ribonuclease.

20 Examples of peptides include metabolic regulation peptides, antimicrobiral peptides, antiviral peptides and antitumor peptides.

25 Examples of lipids include highly unsaturated fatty acids, such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).

Examples of steroids include cholesterol, sex hormones, adrenocortical hormone, sapogenin, and digitoxin.

30 Examples of carotenoids include lycopene, beta-carotene, and lutein.

Examples of sugars include olygosaccharides (e.g.,

05944340-024902

lactose, trehalose, and maltose), polysaccharides (starch, starch hydrolysate, chondroitin sulfate, and hyaluronic acid).

5 Examples of edible plants include plants utilized as vegetables, fruit vegetables, or fruits (e.g., sweet pepper, carrot, tomato, water melon, melon, apple, Amorphophaleus konjac, and blueberry), and plants utilized as medical herbs (e.g., ginseng, ginkgo, Serenoa repens,
10 Momordicae grosvenori, and Garcinia cambogia).

 Examples of edible animals include mammals, birds, reptiles, arthropods, and fish. Examples of a mammal include a pig and a cow. Examples of a bird include a chicken.
15 Examples of a reptile include a soft-shelled turtle, a turtle, and a snake. Examples of an arthropod includes a centipede and a millipede. Examples of fish include an eel.

 Examples of bacteria include bifidobacterium.
20

 Examples of fungi include yeast and mushrooms. Examples of a mushroom include a bracket fungus, a vegetative wasp, and an Agaricus.

25 As described above, the present invention may be utilized preferably as a soft capsule comprising a food exhibiting an unpleasant taste, such as a health food, a functional food and a nutritional supplementary food. The present invention may also be preferably utilized as a soft
30 capsule type nonessential food having a chocolate base taste and giving a peculiar sensation of chewing.

 In the soft capsule of the present invention, the

05914340-021906

shell may comprise the following components (A) and (B):
(A) gelatin; and (B) a total of 100 to 600 weight parts of
a plasticizer with respect to 100 weight parts of the gelatin.
Such a plasticizer is typically one or more selected from
5 (b1) to (b3) below: (b1) glycerin, (b2) a saccharide selected
from the group consisting of sucrose, fructose, D-mannitol,
xylitol, erythritol, D-sorbitol, maltose, reduced maltose
syrup, maltitol, sucrose alcohol and isomerized sugar as
well as a combination thereof (the saccharide is herein
10 referred to as a "saccharide plasticizer"), and (b3) glycol
selected from the group consisting of propylene glycol and
polyethylene glycol as well as a combination thereof.

In the present invention, "gelatin" includes any of
15 gelatin, acidic gelatin, alkaline gelatin, peptidegelatin,
low molecular weight gelatin, and a derivative of gelatin
(e.g., succinylated gelatin). Any of these gelatins can be
used alone or in combination as the component (A) of the
shell of the present invention.

One or more selected from (b1) glycerin, (b2) a
20 saccharide plasticizer, and (b3) glycol may be used as a
plasticizer of the component (B) of a shell. In the present
invention, at least the glycerin (b1) is preferably used
25 as a plasticizer component. Especially when taking into
consideration easiness of molding, the glycerin (b1) is
preferably used in combination with at least one of other
plasticizer components, i.e., the saccharide
plasticizer (b2) and the glycol (b3) .

30 The mix amount of plasticizer in a shell is
preferably a total amount of 100 to 600 weight parts of the
plasticizer with respect to 100 weight parts of gelatin.

When the mix amount is less than 100 weight parts, a capsule is hardened, while when the mix amount exceeds 600 weight parts, a capsule is softened but is likely to be difficult to be molded.

5

When the glycerin (b1) is used alone as the component (B), the amount of the glycerin (b1) used is 100 to 300 weight parts as the component (A), and particularly preferably 120 to 200 weight parts with respect to 100 weight parts of gelatin.

10

In the present invention, as the saccharide plasticizer (b2), one selected from sucrose, fructose, D-mannitol, xylitol, erythritol, D-sorbitol, maltose, reduced maltose syrup, maltitol, sucrose alcohol and isomerized sugar as well as a combination thereof is used. To provide sweetness when chewing, D-sorbitol, sucrose and mannitol are preferable. Considering low adhesiveness when added at a high concentration, D-sorbitol and mannitol are preferable.

15

20

When the glycerin (b1) is used in combination with the saccharide plasticizer (b2), the phase-solubility of glycerin with gelatin is excellent, and the plasticizer concentration in a shell can be increased. When glycerin is used in combination with a saccharide plasticizer, 100 weight parts of gelatin is preferably mixed with 50 to 300 weight parts of glycerin (particularly 50 to 250 weight parts), and 30 to 300 weight parts of the saccharide plasticizer (particularly, 50 to 150 weight parts).

25

30

In the present invention, as the glycol (b3), one selected from propylene glycol and polyethylene glycol is

used. Polyethylene glycol having a weight average molecular weight of 400 to 4000 is particularly preferable. These glycols have a high level of hygroscopicity, and are likely to be difficult to be handled after molding, so that
5 it is preferable that the amount of glycol to be added is not excessively large.

The combined use of the glycerin (b1) and the glycol (b3) allows a considerably soft gelatin shell. When
10 glycerin and propylene glycol are used in combination, 100 weight parts of gelatin are preferably mixed with 40 to 200 weight parts of glycerin (particularly, 50 to 120 weight parts) and 20 to 300 weight parts of propylene glycol (particularly, 40 to 100 weight parts). When glycerin and
15 polyethylene glycol are used in combination, 100 weight parts of gelatin is preferably mixed with 50 to 100 weight parts of glycerin (particularly, 60 to 80 weight parts) and 40 to 200 weight parts of polyethylene glycol (particularly, 50 to 100 weight parts).

20 When the glycerin (b1), the saccharide (b2) and the glycol (b3) are used in combination, 100 weight parts of gelatin is preferably mixed with 50 to 200 weight parts of glycerin (particularly, 60 to 150 weight parts of glycerin),
25 30 to 130 weight parts of saccharide (particularly, 40 to 80 weight parts of saccharide), and 20 to 120 weight parts of glycol (particularly, 50 to 100 weight parts of glycol).

In the soft capsule of the present invention, the
30 shell can comprise water-insoluble cellulose as a component (C) in addition to gelatin as the component (A) and a plasticizer as the component (B). Examples of water-insoluble cellulose include crystalline cellulose, ethyl

09914340-0219000

cellulose, low-substitution-degree hydroxypropyl
cellulose and starch as well as a combination thereof. In
order to prevent soft capsules from adhering to one another,
crystalline cellulose is particularly preferable. The mix
5 amount of water-insoluble cellulose is preferably 5 to 100
weight parts, and more preferably 25 to 75 weight parts with
respect to 100 weight parts of gelatin. When the mix amount
of water-insoluble cellulose is less than 5 weight parts
with respect to 100 weight parts of gelatin, capsules are
10 not sufficiently prevent from adhering to one another. In
this case, such capsules adhere to one another or a container
in preservation, or the capsules tend to cause the sensation
of adhesion in the mouth. When a mix amount of water-
insoluble cellulose exceeds 100 weight parts with respect
15 to 100 weight parts of gelatin, the capsule is likely to
be difficult to be molded.

In the soft capsule of the present invention, the
shell further comprises any sweetening component as a
20 component (D) (herein referred to as a "sweetener"). A
sweetener may be any sweetening substance as long as it is
pharmaceutically acceptable or appropriate to a food, and
is compatible for production of a soft capsule. Preferable
examples of a sweetener include saccharin sodium, stevia
25 and thaumatin as well as any combination thereof.

A sweetener is optionally added to a shell, thereby
making it possible to provide a preparation capable of being
easily chewed in the mouth even if ingested without water.

30

The shell of the soft capsule of the present
invention may optionally comprise a coloring agent, a
preservative, a disintegrator, a surfactant, an aromatic,

05944340-024902

5 a flavor corrective, and a smell corrective other than the
above-described components (A) through (D). Further, a
weight ratio of fill material to shell is typically about
1:1 to about 4:1, preferably about 3:2 to about 3:1, and
a size of a capsule is No. 3 to 20, and preferably No. 5
to 15, in view of improving the ingestion properties.

10 The soft capsule of the present invention may be
produced by any appropriate method including a step of
filling a fill material into a shell. To fill a fill material
into a shell, an apparatus and procedure known in the field
of production of conventional soft capsules can be utilized
(see, e.g., Yamada, The Pharmaceuticals Monthly, Vol. 28,
No. 4, pp. 713 to 717 (1986)).

15 Figure 1 is a process diagram showing an example of
production of the soft capsule of the present invention.
Initially, a chocolate base (or another low melting point
additive) is melted by heating. A mixture of a drug (or food),
20 a sweetening agent and a saccharide, and optionally an
aromatic are added to the melted chocolate base while heating
to obtain a fill material as a uniform suspension.
Separately, a shell material comprising gelatin and a
plasticizer as main components is mixed, and melted by
25 heating. The shell is filled with the fill material, whose
flow property is maintained by heating, and molded, using
an appropriate filling machine (e.g., an automatic rotary
molding machine), optionally followed by drying in a drying
chamber whose temperature is appropriately controlled.
30 Thus, the intended soft capsule is obtained.

When the above-described drying step is continued
at a desired temperature for a predetermined time or more,

03514340-021902

the fill material can experience an aging effect. As used herein, the term "aging" refers to obtaining an improvement in a physicochemical property of the fill material by keeping it at a desired temperature for a predetermined time or more.

5 For example, when a chocolate base, particularly cacao butter, is included in the fill material, the crystal type of the cacao butter in the chocolate base can be controlled by aging.

10 Crystal polymorphism is present in cacao butter. When a cacao butter melt is gradually cooled, V-type and VI-type crystals which are stable forms are crystallized, thereby increasing the hardness of the cacao butter. The VI-type crystal has a hardness greater than that of the
15 V-type crystal, but easily becomes coarse. Therefore, the VI-type crystal has been considered to be responsible for reducing ingestion properties (solubility in the mouth) (Hachiya et al., New Food Industry, 31(9), 65 to 74 (1989); and Hachiya, Yushi, 42, 50 to 58 (1989)).

20 The inventors have found that in production of a soft capsule comprising cacao butter as a low melting point additive, an appropriate amount of VI-type crystal such that the hardness of the cacao butter is increased to an
25 appropriate level while ingestion properties are not reduced is crystallized by aging, so that a sense of homogeneity of the shell and the fill material is further improved. An aging temperature which allows a desired level of hardness is typically 20 to 40°C, preferably 25 to 40°C,
30 more preferably 30 to 40°C, even more preferably 32 to 38°C, and further preferably about 35°C. The time required for aging is commonly 5 hours or more, preferably 10 hours or more, and more preferably 15 hours or more. Although there

09014340-024502

is not particularly an upper limit to the aging time, the effect of the aging time is saturated beyond a predetermined time.

5 Therefore, in a preferred embodiment of the present invention, cacao butter which is included in the fill material as a low melting point additive includes a major amount of V-type crystal and a minor amount of VI-type crystal. Here, "major amount" refers to an amount of
10 crystal of a type which is present most predominantly in cacao butter crystals which is observable using X-ray diffraction. "Minor amount" refers to an amount of crystal whose present amount is relatively smaller than the major amount but is still more than or equal to a lower limit which
15 is observable by X-ray diffraction.

Control of crystal types by aging can be applied to a case where bitter chocolate including a small amount of cacao butter is used as a low melting point additive, and
20 further to a case where a low melting point additive other than cacao butter, which exhibits crystal morphism, is used.

The thus-obtained soft capsule of the present invention can be used preferably as a medicament, a
25 preparation, and various foods such as a confection and a health food.

(Examples)

Hereinafter, specific examples of the present
30 invention will be further disclosed. The scope of the present invention is not limited by these examples.

(Production of Soft Capsule)

All of soft capsules according to an example were produced as follows:

5 A chocolate base (or an alternative) was melted at about 40°C. A drug, a saccharide, a sweetening agent, and optionally an aromatic were suspended in the chocolate base while maintained at about 40°C by heating. Thus, the fill materials were prepared. A shell was prepared by melting
10 gelatin, a plasticizer, and optionally a sweetener at about 60°C. The shell was filled with the fill material and molded using an automatic rotary molding machine (manufactured by LEINER & SONS), followed by drying in a drying chamber at 20 to 35°C (at a humidity of about 10 to 30%). Thus, each soft capsule was produced.

15

(Evaluation Method for Testing Taste)

All of taste tests were conducted for the soft capsules of the examples as follows:

20 Five volunteers were used as subjects. A first specimen was ingested by them without water and the taste was evaluated. Four hours after ingesting the first specimen, a second specimen was similarly ingested and evaluated. If there were third and fourth specimens, these specimens were ingested without water in the next day at
25 an interval of four hours, and evaluated. If there was a fifth specimen, the specimen was ingested without water in the further next day, and evaluated. (Specimens listed on tables below were successively referred to as a first specimen, a second ... from right to left.) Tastes of the
30 specimens were evaluated in accordance with a criterion indicated in Table 1 below.

09044340-0219002

Table 1

Criteria (five levels)		
Item	Level	Criteria
Unpleasant sensation of shell Bitterness of fill material	1	present
	2	slightly present
	3	intermediate
	4	almost none
	5	none
Total Sensation of ingestion	1	bad
	2	slightly bad
	3	intermediate
	4	good
	5	considerably good

(Production Examples 1 to 5: Study of Base)

5 Fill materials each having a formulation indicated in Table 2 were produced by the above-described method without capsulation.

Table 2

10

Fill material formulation (mg)	C.Ex.1	P.Ex.1	P.Ex.2	P.Ex.3	P.Ex.4	P.Ex.5
Acetaminophen	60	60	60	60	60	60
Bitter chocolate	-	-	-	50	-	25
Cacao powder	-	-	-	-	50	25
Medium chain fatty acid triglyceride	170	-	85	-	-	-
Cacao butter	-	170	85	120	120	120
Xylitol	60	60	60	60	60	60
Total	290	290	290	290	290	290

15 Results of the taste test are shown in Table 3 as averages of the judgements by the five volunteers. Comparative Example 1 as well as Production Examples 1 and 2 were separately evaluated from Production Examples 3 to

5.

Table 3

Item of Taste test	Average		
	C.EX.1	P.Ex.1	P.Ex.2
Bitterness of fill material	1.0	2.6	1.4
Total sensation of ingestion	1.2	2.8	1.8

5

Item of Taste test	Average		
	P.EX.3	P.Ex.4	P.Ex.5
Bitterness of fill material	3.2	3.6	3.4
Total sensation of ingestion	3.6	3.0	3.0

10 In Comparative Example 1 using an oil base (medium chain fatty acid triglyceride) which is a conventional formulation, the bitterness of a drug and the oiliness peculiar to the oil base were sensed immediately after ingestion, so that the sensation of ingestion was considerably bad. In Production Example 2 in which equal amounts of an oil base and cacao butter were added as a part of the fill material, the fill materials were in a semi-solid form, and the sensation of ingestion was slightly improved. 15 In Production Example 1 in which only cacao butter as a chocolate base was added as a part of the fill materials, the fill materials were in a solid form, and bitterness and oiliness were not significantly sensed in ingesting the capsule. 20

Based on a formulation of Production Example 1 exhibiting a satisfactory sensation of ingestion as indicated above, bitter chocolate and/or cacao powder 25 having a bitter taste among chocolate bases were used. In

20544340-021902

5 this case, the bitterness of a drug was further suppressed, and the sensation of ingestion was improved (Production Example 3 to 5). Among Production Examples 3 to 5, Production Example 3 using bitter chocolate alone was the most satisfactory.

(Production Examples 6 to 13: Study of Sweetening Agents and Aromatics)

10 Fill materials of each formulation indicated in Table 4 were produced in a manner similar to that of Production Example 1 and the like.

Table 4

Fill material formulation (mg)

	P.Ex.6	P.Ex.7	P.Ex.8	P.Ex.9	P.Ex.10	P.Ex.11	P.Ex.12	P.Ex.13
Acetaminophen	60	60	60	60	60	60	60	60
Bitter chocolate	50	50	50	50	50	50	50	50
Cacao butter	120	120	120	120	120	120	120	120
Xylitol	60	60	60	60	60	60	60	60
Aspartame	10	-	-	-	-	10	10	10
Saccharin sodium	-	3	-	-	-	-	-	-
Thaumatococcus	-	-	1	-	-	-	-	-
Dipotassium glycyrrhizinate	-	-	-	5	-	-	-	-
Stevia	-	-	-	-	14	-	-	-
Chocolate flavor	-	-	-	-	-	0.3	-	-
Peppermint flavor	-	-	-	-	-	-	0.3	-
Vanilla flavor	-	-	-	-	-	-	-	0.3
Total	300	293	291	295	304	300.3	300.3	300.3

15

Results of the taste test are shown in Table 5 as averages of the judgements by the five volunteers. Production Examples 6 to 10 were separately evaluated from Production Examples 11 to 13.

20

09514340-024902

[illegible]

Item of taste test	Average		
	P.Ex.11	P.Ex.12	P.Ex.13
Bitterness of fill material	4.6	4.4	3.8
Total sensation of ingestion	4.8	4.0	4.2

20 (Production Example 14 to 18: Study of Drug Content)
Fill materials of each formulation indicated in
Table 6 were produced in a manner similar to that of
Production Example 1 and the like.

25

Table 6

Fill material formulation (mg)

	P.Ex.14	P.Ex.15	P.Ex.16	P.Ex.17	P.Ex.18
Acetaminophen	60	103	160	240	360
Bitter chocolate	50	50	50	50	50
Cacao butter	180	180	180	180	180
Aspartame	10	10	10	10	10
Total	300	343	400	480	600
Main drug concentration (%)	20.0	30.0	40.0	50.0	60.0

5 As described above, five volunteers were used to conduct a taste test (the result is not shown).

10 Acetaminophen having a relatively strong bitterness was used to study the main drug concentration which causes strong sensation of bitterness. Bitterness was somewhat suppressed until the main drug concentration is up to 50% (Production Example 17). Among these Production Examples, bitterness could be significantly suppressed when the main drug concentration was 20% (Production Example 14).

15 (Production Examples 19 to 24: Study of Stability of Aspartame as Sweetening Agent)

20 Fill materials of each formulation indicated in Table 7 were produced in a manner similar to that of Production Example 1 and the like.

03914340.024902

Table 7

Fill material formulation (mg)						
	P.Ex.19	P.Ex.20	P.Ex.21	P.Ex.22	P.Ex.23	P.Ex.24
Acetaminophen	60	60	60	60	60	60
Bitter chocolate	10	50	80	110	140	370
Cacao butter	160	120	90	60	30	-
Xylitol	60	60	60	60	60	60
Aspartame (APT)	10	10	10	10	10	10
Total	300	300	300	300	300	500
Mix proportion of cacao butter (%)	53.3	40.0	30.0	20.0	10.0	0.0
Residual rate of APT to initial value (%) 45°C to one month	93.1	96.9	98.2	98.3	97.6	91.0

5 In Production Example 20, Production Example 6 as described above was prepared again and subjected to a temporal stability test (45°C, one month). Further, the mix proportion of cacao butter was changed and studied similarly. When the mix proportion of cacao butter was 10% or more of the weight of the fill materials, the temporal stability of aspartame could be secured. Further, when the mix proportion of cacao butter was 0% in Production Example 24, a residual rate of aspartame with respect to an initial value was secured up to about 91%. Therefore, the possibility that a sufficient aspartame content is secured when the mix proportion of cacao butter is 10% or more, was demonstrated.

(Production Examples 25 to 28: Differentiation between Semi-solid and Solid Contents)

20 Fill materials of each formulation indicated in Table 8 were produced in a manner similar to that of Production Example 1 and the like. Forms of the fill

05914340-051900

materials were observed at a standard temperature (about 20°C).

Table 8

5

Fill material formulation (mg)				
	P.Ex.25	P.Ex.26	P.Ex.27	P.Ex.28
Acetaminophen	60	60	60	60
Medium chain fatty acid triglyceride	-	60	63	135
cacao butter	120	78	76	25
bitter chocolate	50	32	31	10
xylitol	60	60	60	60
aspartame	10	10	10	10
Total	300	300	300	300
Proportion of low melting point additive (%)	56.7	36.7	35.7	11.7
Form of fill material	Solid	Solid	Semi-solid	Semi-solid

10 Even if, as a base, a liquid oil base, such as medium chain fatty acid triglyceride was combined with the low melting point additives, the form of the fill materials was semi-solid when an added amount of low melting point additives, such as cacao butter and bitter chocolate, was about 10% to about 36% of the overall fill materials, and was completely solid when the amount was about 36% or more.

15 (Examples 1 to 3: General Evaluation of Soft Capsule)

20 Oval-type soft capsules (No. 7.5) were produced from fill materials and a shell each having a formulation indicated in Table 9. Conditions of drying after molding were a temperature of 25°C, a humidity of 20%, and a duration of 64 hours in Examples 1 to 7.

2006T20-04E4560

Table 9

Formulation (mg/capsule)	C.Ex2	Ex.1	Ex.2	Ex.3
Acetaminophen	60	60	60	60
Medium chain fatty acid triglyceride	170	-	-	-
Cacao butter	-	170	120	120
Bitter chocolate	-	-	50	50
Xylitol	60	60	60	60
Aspartame	10	10	10	10
Chocolate flavor	0.3	0.3	0.3	0.3
Gelatin	70	70	70	70
Concentrated glycerin	95	95	95	95
Saccharin sodium	-	-	-	2
Total	465.3	465.3	465.3	467.3

5 Results of taste tests are shown as averages of the judgements of the five volunteers in Table 10.

Table 10

Item of taste test	Average			
	C.Ex.2	Ex.1	Ex.2	Ex.3
Unpleasant sensation of shell	1.4	2.6	4.0	4.8
Bitterness of fill material	1.2	1.8	4.2	4.4
Total sensation of ingestion	1.2	2.2	4.2	4.6

10 In Comparative Example 2, the fill materials were in a liquid form, so that an unpleasant sensation from the shell was present, and the sensation of ingestion tended to be considerably poor. In Example 1 in which the fill materials included cacao butter and was in a solid form, 15 although the unpleasant sensation from the shell was alleviated, a bitterness of the drug still remained slightly,

and the sensation of ingestion was relatively poor. In Example 2 in which the fill materials additionally included bitter chocolate, bitterness was suppressed, and the sensation of ingestion was considerably improved. Further, it was demonstrated that when a sweetener was added to the shell (Example 3), the sensation of ingestion was further improved.

(Examples 4 to 7: General Evaluation of Rhinitis Drug Formulation)

Oval-type soft capsules (No. 7.5) were produced from fill materials and a shell having a formulation indicated in Table 11.

Table 11

Formulation (mg/capsule)	Ex.4	Ex.5	Ex.6	Ex.7
Phenylpropanolamine hydrochloride	24.75	24.75	24.75	24.75
Belladonna leaf alkaloids	0.25	0.25	0.25	0.25
D-chlorpheniramine maleate	1.2	1.2	1.2	1.2
Dipotassium glycyrrhizinate	7.4	7.4	7.4	7.4
Anhydrous caffeine	20.0	20.0	20.0	20.0
Cacao butter	250	175	125	125
Bitter chocolate	-	75	125	125
Xylitol	60	60	60	60
Aspartame	10	10	10	10
Chocolate flavor	0.3	0.3	0.3	0.3
Gelatin	90	90	90	90
Concentrated glycerin	130	130	130	130
Saccharin sodium	-	-	-	2
Total	593.9	593.9	593.9	595.9

Results of taste tests are shown as averages of the

judgements of the five volunteers in Table 12.

Table 12

Item of taste test	Average			
	Ex.4	Ex.5	Ex.6	Ex.7
Unpleasant sensation of shell	2.6	3.2	4.2	4.8
Bitterness of fill material	1.6	2.8	4.4	4.6
Total sensation of ingestion	2.0	3.4	4.4	4.8

5

In Example 4, the main fill material was cacao butter, so that the unpleasant sensation from the shell was not considerably sensed, but bitterness of a drug slightly remained, and the sensation of ingestion was relatively poor. In Examples 5 and 6 in which bitter chocolate was further included in the fill material, bitterness was suppressed, and the sensation of ingestion was considerably improved. Among the examples, in Example 6 in which the amount of bitter chocolate added was increased, bitterness was further suppressed, and the sensation of ingestion is improved. In Example 7 in which a sweetener was added to the shell, it was demonstrated that the sensation of ingestion was further improved similarly to Example 3 above.

20

(Criterion of Usability)

Usability of soft capsules was evaluated in the following examples in accordance with a criterion indicated in Table 13 below.

25

0594340-024902

Table 13

Criterion for usability		
Item of test	Level	Criterion
Usability	1	Bad
Ease of removing capsule from PTP package by pressing	2	Slightly bad
	3	Intermediate
	4	Good
	5	Considerably good

5 (Examples 8 to 11: General Evaluation of Formulation including Water-insoluble cellulose)

(a) Antipyretic analgesic drug formulation

Oval-type soft capsules (No. 7.5) were produced from fill materials and a shell each having a formulation indicated in Table 14.

10

Table 14

Formulation
(mg/capsule)

	Ex.8	Ex.9	C.Ex.3
Acetaminophen	53.6	53.6	53.6
Medium chain fatty acid triglyceride	-	-	250
Cacao butter	150.0	175.0	-
Bitter chocolate	100.0	-	-
Cacao powder	-	75.0	-
Xylitol	80.0	80.0	80.0
Aspartame (APT)	15.0	15.0	15.0
Chocolate flavor	0.4	0.4	0.4
Succinylated gelatin	70	70	70
Concentrated glycerin	90	90	90
Crystalline cellulose	25	25	25
Titanium oxide	0.34	0.34	0.34
Red No. 102	0.55	0.55	0.55
Yellow No. 5	0.14	0.14	0.14
Blue No. 1	0.02	0.02	0.02
Total	585.05	585.05	585.05

06914340-024902

Results of taste tests and usability tests are shown as averages of the judgements of the five volunteers in Table 15.

5

Table 15

Item of taste test and usability test	Average		
	Ex.8	Ex.9	C.Ex.3
Unpleasant sensation of shell	4.8	4.8	1.4
Bitterness of fill material	4.4	4.6	1.6
Total sensation of ingestion	4.6	4.6	1.2
Usability	4.6	4.6	1.2

10 In Comparative Example 3, since the fill materials were in a liquid form, an unpleasant sensation from the shell was present, and the sensation of ingestion tended to be poor. The soft capsule of Comparative Example 3 tended to be significantly difficult to remove from a PTP (Press Through Pack) package by pressing.

15 In Examples 8 and 9, cacao butter was used as a base, and bitter chocolate or cacao powder was added to the fill materials, so that the fill materials were in a solid form. In the examples, the unpleasant sensation from the shell was alleviated, bitterness was further suppressed, and the
 20 sensation of ingestion was considerably improved. In Examples 8 and 9, a shell of soft capsules included crystalline cellulose which is a kind of water-insoluble cellulose. For the soft capsules of examples 8 and 9, an unpleasant sensation from the capsules was substantially
 25 not present. In observation in a sealed glass bin at 40°C for one month storage, the capsules substantially did not

adhere to one another. Further, the solid form of the fill materials allowed the soft capsule to be easily removed from a PTP package by pressing. Therefore, it was demonstrated that the formulations of Examples 8 and 9 are excellent products from a viewpoint of practical utility.

(b) Rhinitis Drug Formulation

Oval-type soft capsules (No. 7.5) were produced from fill materials and a shell having a formulation indicated in Table 16.

Table 16

Formulation
(mg/capsule)

	Ex.10	Ex.11
Phenylpropanolamine hydrochloride	24.75	24.75
Belladonna leaf alkaloids	0.25	0.25
Dipotassium glycyrrhizinate	7.4	7.4
Anhydrous caffeine	20.0	20.0
D-chlorpheniramine maleate	1.2	1.2
Cacao butter	150.0	175.0
Bitter chocolate	100 .0	-
Cacao powder	-	75.0
Xylitol	80.0	80.0
Aspartame(APT)	15.0	15.0
chocolate flavor	0.4	0.4
Succinylated gelatin	70	70
Concentrated glycerin	90	90
Crystalline cellulose	25	25
Titanium oxide	0.34	0.34
Red No. 102	0.55	0.55
Yellow No. 5	0.14	0.14
Blue No. 1	0.02	0.02
Total	585.05	585.05

Results of taste tests and usability tests are shown as averages of the judgements of the five volunteers in Table 17.

5 Table 17

Item of taste test and usability test	Average	
	Ex.8	Ex.9
Unpleasant sensation of shell	4.8	4.8
Bitterness of fill material	4.4	4.6
Total sensation of ingestion	4.6	4.6
Usability	4.6	4.6

10 In rhinitis drug formulations of Examples 10 and 11, similarly to Examples 8 and 9 above, the unpleasant sensation from the shell was alleviated, bitterness was suppressed, and the total sensation of ingestion was significantly satisfactory. Usability was also evaluated highly. Therefore, it was demonstrated that the formulations of Examples 10 and 11 are excellent products from a viewpoint of practical utility.

15

(Production Example 29 and 30: Study of Aging)

(a) Study of aging temperature

20 The same formulation fill materials as those in Example 8 (Production Example 29) were prepared and melted in a manner similar to that of Production Example 1 above or the like. Thereafter, the resultant fill materials were subjected to aging in a drying chamber at 25°C, 30°C, 35°C, 37°C, and 40°C for 16 hours. As a control, cacao butter alone was solely subjected to the same procedure. After aging, the fill materials were cooled and solidified in the shape

25

of a capsule. Hardness of the solidified fill materials and cacao butter in a minor axis direction of breadth was measured using a manual tablet hardness tester (manufactured by Pfizer Inc.).

5

Results are shown in Figure 2. The hardness of the capsule fill materials and cacao butter were both gradually increased with an increase in aging temperature. The hardness reached a peak at 35°C and tended to fall at higher
10 temperatures. The change in hardness of the capsule fill materials and the change in hardness of cacao butter alone had the same temperature dependent pattern. Therefore, it was demonstrated that a physical property of cacao butter is a dominant cause for an increase in hardness of the capsule
15 fill materials. In this case, cacao butter subjected to aging at 35°C included mainly V-type crystal and subordinately VI-type crystal according to X-ray diffraction analysis.

20

(b) Study of Aging time

The same fill materials as those in Example 8 (Production Example 30) were prepared and melted in a manner similar to that of Production Example 1 above or the like. Thereafter, the resultant fill materials were subjected to
25 aging in a drying chamber at 35°C for 0, 2, 6, 8, 12, 16 and 64 hours. As a control, cacao butter alone was solely subjected to the same procedure. After aging, the fill materials and cacao butter were cooled and made solid in the shape of a capsule. The hardness of solidified fill
30 materials and cacao butter was measured in a manner similar to that of above section (a).

Results are shown in Figure 3. The hardness of the

capsule fill materials and cacao butter were both gradually increased with an increase in aging time until 16 hours. After 16 hours and 64 hours, no further difference was found. Therefore, it was demonstrated that a near-maximal hardness is obtained by aging at 35°C for 16 hours or more.

(Example 12: General Evaluation of Aged Soft Capsule)

Soft capsules were produced using the same fill materials and shell as those in Example 8. After molding, a first group of the soft capsules were subjected to aging at 35°C for 16 hours (Example 12), and a second group of the soft capsules were not subjected to aging but were cooled at 25°C (Example 13). Each of the resultant soft capsules were subjected to a taste test and a usability test.

Results are shown in Figure 4. As compared to the non-aged soft capsules, the aged soft capsules had a further alleviated unpleasant sensation from the shell, further suppressed bitterness of the drug, and improved evaluation of the total sensation of ingestion and usability. Therefore, it was demonstrated that when the fill materials of a formulation include cacao butter, aging allows an especially satisfactory soft capsule.

INDUSTRIAL APPLICABILITY

According to the present invention, the fill materials of a soft capsule are formulated in such a manner as to be in a solid or semi-solid form at room temperature. Therefore, when chewing the soft capsule, the shell and the fill materials are homogenized, thereby making it possible to alleviate the unpleasant sensation from the shell.

Particularly, when a low melting point additive, such as a chocolate base, are formulated as a fill material of the soft capsule, a preparation capable of being easily chewed in the mouth without water is obtained. Such a chewable soft capsule is useful as an immediate-soluble drug and food, especially for children or elderly users.

When fill materials are in a solid form, a soft capsule containing a fill material can be easily removed from a packaging container, resulting in satisfactory usability. When a shell includes water-insoluble cellulose, the effect that capsules are unlikely to adhere to one another in preservation is obtained. Thus, the present invention can provide a soft capsule having practical utility as a product.

When a soft capsule is subjected to aging after a shell is filled with fill materials, the sensation of ingestion and usability can be particularly improved in a case where a chocolate base, particularly cacao butter, is used as a low melting point additive.

Amended Claims 1-33 Submitted to IPEA on Nov 20, 2000
Under Article 34

- 5 1. A soft capsule comprising fill material filling a shell,
wherein the fill material is in a solid or semi-solid form
at room temperature.
- 10 2. A soft capsule according to claim 1, wherein the soft
capsule is a chewable capsule.
- 15 3. A soft capsule according to claim 1, wherein the fill
material comprises a low melting point additive.
- 20 4. A soft capsule according to claim 3, wherein the content
of the low melting point additive is 10% or more with respect
to the total weight of the fill material.
- 25 5. A soft capsule according to claim 4, wherein the content
of the low melting point additive is 30% or more with respect
to the total weight of the fill material.
6. A soft capsule according to claim 5, wherein the content
of the low melting point additive is 50% or more with respect
to the total weight of the fill material.
7. A soft capsule according to any of claims 3 to 6, wherein
the melting point of the low melting point additive is about
20 to 50°C.
- 30 8. A soft capsule according to any of claims 3 to 6, wherein
the low melting point additive is selected from the group
consisting of chocolate base, lard, coconut oil and macrogol
as well as a combination thereof.

09/914340-094002

9. A soft capsule according to claim 8, wherein the low melting point additive is a chocolate base.

5 10. A soft capsule according to claim 9, wherein the chocolate base is selected from the group consisting of cacao powder, bitter chocolate and cacao butter as well as a combination thereof.

10 11. A soft capsule according to claim 10, wherein the cacao butter includes a major amount of V-type crystal and a minor amount of VI-type crystal.

15 12. A soft capsule according to claim 1 or 3, wherein the fill material further comprises a sweetening agent.

20 13. A soft capsule according to claim 12, wherein the sweetening agent is selected from the group consisting of aspartame, disodium glycyrrhizinate, saccharin sodium, stevia and thaumatin as well as a combination thereof.

25 14. A soft capsule according to claim 13, wherein the fill material comprises cacao butter as chocolate base, which is a low melting point additive, and aspartame as a sweetening agent.

15. A soft capsule according to claim 12, wherein the fill material further comprises a saccharide.

30 16. A soft capsule according to claim 15, wherein the saccharide is selected from the group consisting of sucrose, D-mannitol, xylitol, erythritol, D-sorbitol, maltose, reduced maltose syrup and maltitol as well as a combination

05944340-021902

thereof.

17. A soft capsule according to claim 12, wherein the fill material further comprises an aromatic.

5

18. A soft capsule according to claim 17, wherein the aromatic is chocolate flavor.

19. A soft capsule according to any of claims 1 to 18,
10 wherein

the shell comprises the following components (A) and (B):

(A) gelatin; and

(B) one or more plasticizers selected from (b1) to
15 (b3), wherein a total of 100 to 600 weight parts of the plasticizers is present in the shell with respect to 100 weight parts of gelatin:

(b1) glycerin,

(b2) saccharide plasticizer selected from the
20 group consisting of sucrose, fructose, D-mannitol, xylitol, erythritol, D-sorbitol, maltose, reduced maltose syrup, maltitol, sucrose alcohol and isomerized sugar as well as a combination thereof, and

(b3) glycol selected from the group consisting of
25 propylene glycol and polyethylene glycol as well as a combination thereof.

20. A soft capsule according to claim 19, wherein the plasticizers (B) include the glycerin (b1).

30

21. A soft capsule according to claim 19, wherein the shell further comprises (C) water-insoluble cellulose, wherein 5 to 100 weight parts of water-insoluble cellulose is present

09914340-021902

in the shell with respect to 100 weight parts of the gelatin.

22. A soft capsule according to claim 19, wherein the shell further comprises (D) a sweetener.

5

23. A soft capsule according to claim 22, wherein the sweetener (D) is selected from the group consisting of saccharin sodium, stevia and thaumatin as well as a combination thereof.

10

24. A soft capsule according to any of claims 1 to 23, wherein the fill material comprises a drug.

15

25. A soft capsule according to claim 24, wherein the content of the drug is 60% or less with respect to the total weight of the fill material.

20

26. A soft capsule according to claim 25, wherein the drug is selected from the group consisting of an antipyretic analgesic drug component, a rhinitis drug component, an antitussive expectorant drug component and a vitamin component as well as a combination thereof.

25

27. A soft capsule according to any of claims 1 to 23, wherein the fill material comprises a food.

28. A method for producing a soft capsule according to any of claims 1 to 27, comprising the step of:

filling the shell with the fill material.

30

29. A method according to claim 28, wherein the fill material comprises cacao butter as chocolate base, which is a low melting point additive, and the method further

09914340-021902

comprises the step of:

subjecting the fill material filling in the shell to aging at a temperature of 30 to 40°C.

5 30. A method according to claim 29, wherein the aging is conducted for 10 hours or more.

31. (Added) A soft capsule according to claim 8, wherein the low melting point additive is lard.

10

32. (Added) A soft capsule according to claim 8, wherein the low melting point additive is coconut oil.

15

33. (Added) A soft capsule according to claim 8, wherein the low melting point additive is macrogol.

05944340-024902

FIG. 1




FIG. 2




FIG. 3





FIG. 4

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CHEWABLE SOFT CAPSULE HAVING IMPROVED INGESTION
PROPERTY AND METHOD FOR PRODUCING SAME

the specification of which was filed on February 23, 2000
and possesses PCT International Application No. PCT/JP00/01049
and was amended on November 20, 2000 (Article 34)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37 Code of Federal Regulations § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119(a) - (d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Japanese Patent Application No. 11-51411
Filed on February 26, 1999

2006.02.20.04.40.00

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any U.S. provisional application(s): Not applicable.

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT international application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Richard M. Klein

Registration No. 33,000

Direct all telephone calls to: Richard M. Klein at telephone number: (216) 861-5582.

Address all correspondence to:

Richard M. Klein

Fay, Sharpe, Fagan, Minnich & McKee, LLP

1100 Superior Avenue, Seventh Floor

Cleveland, Ohio 44114

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2025 FEB 20 04:44:50

100 Full name of first inventor: Hidekazu SHODAI

Inventor's signature Hidekazu Syodai

Date: September 26, 2001

Residence: JAPAN

Citizenship: Japanese

Post Office Address: **6-14, Makamicho 4-chome,
Takatsuki-shi, Osaka 569-1121 Japan**

2-00 Full name of second inventor: Noboru NAGAFUJI

Inventor's signature noboru nagafuji

Date: October 2, 2001

Residence: JAPAN

Citizenship: Japanese

Post Office Address: **355-2, Otorinakamachi 9-cho,
Sakai-shi, Osaka 593-8327 Japan**

300 Full name of third inventor: Toshitada TOYODA

Inventor's signature Toshitada TOYODA

Date: September 26, 2001

Residence: JAPAN

Citizenship: Japanese

Post Office Address: **114-8, Befu, Ikawadanicho, Nishiku,
Kobe-shi, Hyogo 651-2115 Japan**

400 Full name of fourth inventor: Yuka OKADA

Inventor's signature Yuka OKADA

Date: October 10, 2001

Residence: JAPAN

Citizenship: Japanese

Post Office Address: **23-11, Shimotanabecho 1-chome,
Takatsuki-shi, Osaka 569-0062 Japan**